1. Home
  2. XNCR vs GUG Comparison

XNCR vs GUG Comparison

Compare XNCR & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XNCR
  • GUG
  • Stock Information
  • Founded
  • XNCR 1997
  • GUG 2021
  • Country
  • XNCR United States
  • GUG United States
  • Employees
  • XNCR N/A
  • GUG N/A
  • Industry
  • XNCR Biotechnology: Pharmaceutical Preparations
  • GUG Trusts Except Educational Religious and Charitable
  • Sector
  • XNCR Health Care
  • GUG Finance
  • Exchange
  • XNCR Nasdaq
  • GUG Nasdaq
  • Market Cap
  • XNCR 547.8M
  • GUG 470.0M
  • IPO Year
  • XNCR 2013
  • GUG N/A
  • Fundamental
  • Price
  • XNCR $8.60
  • GUG $15.96
  • Analyst Decision
  • XNCR Buy
  • GUG
  • Analyst Count
  • XNCR 10
  • GUG 0
  • Target Price
  • XNCR $23.33
  • GUG N/A
  • AVG Volume (30 Days)
  • XNCR 700.0K
  • GUG 108.9K
  • Earning Date
  • XNCR 11-05-2025
  • GUG 01-01-0001
  • Dividend Yield
  • XNCR N/A
  • GUG 9.67%
  • EPS Growth
  • XNCR N/A
  • GUG N/A
  • EPS
  • XNCR N/A
  • GUG N/A
  • Revenue
  • XNCR $146,929,000.00
  • GUG N/A
  • Revenue This Year
  • XNCR $22.06
  • GUG N/A
  • Revenue Next Year
  • XNCR N/A
  • GUG N/A
  • P/E Ratio
  • XNCR N/A
  • GUG N/A
  • Revenue Growth
  • XNCR N/A
  • GUG N/A
  • 52 Week Low
  • XNCR $6.92
  • GUG $12.71
  • 52 Week High
  • XNCR $27.24
  • GUG $15.06
  • Technical
  • Relative Strength Index (RSI)
  • XNCR 57.89
  • GUG 54.77
  • Support Level
  • XNCR $8.25
  • GUG $15.97
  • Resistance Level
  • XNCR $8.73
  • GUG $16.25
  • Average True Range (ATR)
  • XNCR 0.38
  • GUG 0.19
  • MACD
  • XNCR 0.07
  • GUG 0.02
  • Stochastic Oscillator
  • XNCR 78.76
  • GUG 56.06

About XNCR Xencor Inc.

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

About GUG Guggenheim Active Allocation Fund of Beneficial Interest

Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.

Share on Social Networks: